A study in this issue of Molecular Pharmacology on agonist-induced internalization of mu-opioid receptors during chronic opiate drug exposure is discussed. The study demonstrates the critical role of re-cycling of reactivated mu receptors back to the plasma membrane for the maintenance of agonist signaling during chronic opiate exposure.
This article has not been copyedited and formatted. The final version may differ from this version. and Ca 2+ ion channels. Following activation of MOP-r by full agonists such as the enkephalin analog DAMGO or the synthetic drug sufentanil, the receptor is phosphorylated and then internalized. These processes are linked but can be separated (Celver et al, 2004 ; see Perspective by Cox & Crowder, 2004) . Internalization of the receptor removes a significant fraction of functional MOP-r from the plasma membrane and thus may contribute in part to the loss of agonist signaling (tolerance) induced by high or sustained agonist exposures (Whistler et al, 1999) . Receptor phosphorylation after exposure to morphine and some other clinically useful analgesics occurs at a much slower rate than after exposure to full agonists, and morphine induces little internalization of the receptor (Keith et al, 1996; Alvares et al, 2002) . Once internalized after full agonist exposure, a region of the MOP-r sequence directs the internalized receptors to a recycling pathway that ultimately returns de-phosphorylated receptors back to the plasma membrane with restored functionality where they are immediately available to re-initiate agonist signaling (Tanowitz & von Zastrow, 2003) . It has been unclear whether this recycling process is rapid enough to permit recovery of signaling during a single exposure to high concentrations of full agonist. A paper in the current issue of Molecular Pharmacology now sheds further light on the role of agonist-induced internalization of MOP-r in maintaining agonist signaling (Koch et al, 2004 ). These results strongly suggest that within the 60 min period of pre-incubation with agonists, a substantial fraction of internalized desensitized MOP-r are returned to the plasma membrane as reactivated receptors, while non-internalizing agonists induce an accumulation of non-functional desensitized receptors on the plasma membrane surface.
However interpretation of these results is complicated by the presence of spare receptors in this system since the drugs that induced relatively little internalization of MOP-r are known from other studies to be partial agonists at MOP-r. It is possible that a high degree of desensitization might simply be a consequence of partial agonism. Koch et al (2004) therefore re-evaluated MOP-r desensitization when recycling of the internalized MOP-r to the plasma membrane was prevented by co-incubation with monensin, an agent that raises endosome pH and thus prevents recycling of internalized receptors (Benzi et al, 1997; Baratti-Elbaz et al, 1999; Leterrier et al, 2004) . In the presence of monensin, receptor-internalizing full agonists such as DAMGO, or agonists with intermediate ability to internalize MOP-r such as methadone, produced a significantly greater desensitization than in its absence, a level of desensitization that was similar to that observed with morphine, a partial agonist, in the absence of monensin. Thus, prevention of receptor recycling after full agonist exposure results in a level of desensitization comparable to that observed with non-internalizing partial agonists.
Another possible explanation of the inverse correlation between desensitization and internalization observed by Koch et al (2004) is that the reduction of agonist A critical question is whether these results can be transferred to the regulation of endogenous MOP-r in normal neurons. Each of the adaptive processes studied by Koch et al (2004) , including agonist-induced desensitization of MOP-r, receptor internalization, recycling of reactivated MOP-r to the plasma membrane, and agonist-induced upregulation of cAMP pathways, have been observed in MOP-r expressing neurons in the central nervous system of rat and other species (Trafton et al, 2000; Alvarez et al, 2002) . Thus the detailed events documented in the model system used by Koch et al (2004) are probably relevant to the actions of opiate drugs acting on MOP-r in neurons in vivo. The recycling pathway for MOP-r appears similar to that utilized by several other GPCR, including β 2 -adrenergic receptors (Tsao & von Zastrow, 2000) , the TSH receptor (Baratti-Elbaz et al, 1999) , and CB1 cannabinoid receptors (Leterrier et al, 2004) . clinically useful agonists at MOP-r. The reduced loss of agonist signaling observed after treatment with DAMGO or etonitazine (relative to morphine) might suggest that these drugs would be more effective as analgesic agents than the rapidly desensitizing agents, morphine, hydromorphone, oxycodone or pethidine. In practice, however, morphine and related drugs retain a clinically useful degree of agonist potency as analgesics over days or weeks despite the high level of desensitization of MOP-r that they can induce. This may be related to the presence of an excess of MOP-r (spare receptors) in opiateregulated pain pathways (Zernig et al, 1995 (Zernig et al, , 1997 . Therapeutic doses of morphine can apparently activate a sufficient percentage of MOP-r at strategic sites on nociceptive pathways to provide effective modulation of pain perception even though a significant fraction of receptors activated by morphine are desensitized. Internalizing agonists such as DAMGO, sufentanil or etonitazine, may give better retention of agonist signaling in the short-term, but may also induce more marked superactivation of compensatory pathways, including enhanced AC activity, that would at later time points indirectly reduce the effectiveness of MOP-r activation and also induce increased physical dependence. DAMGO, a peptide, does not readily enter the CNS, limiting its usefulness for therapeutic purposes. Etonitazine, a potent analgesic in rodents, is also not used clinically. Sufentanil and closely related drugs are used in the clinic primarily as potent anesthetic agents for relatively short procedures and for regional analgesia in child-birth, not as systemic analgesics for pain relief over periods of many days. This is largely because of their rapid elimination in vivo, although a recent study has shown that continuously administered sufentanil can provide moderate pain relief over periods as long as 16 hrs (Reynolds et al, 2004) . Any possible clinical relevance of the interesting results reported by Koch et al (2004) will require further study in more complex neuronal systems where the additional modulating influences of trans-synaptic adaptations can also be evaluated.
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